دورية أكاديمية
أعرض في EDS

Clinical Features and the Outcome Evaluations of Keloid and Hypertrophic Scar Treatment with Triamcinolone Injection in Mekong Delta, Vietnam - A Cross-Sectional Study.

التفاصيل البيبلوغرافية
العنوان: Clinical Features and the Outcome Evaluations of Keloid and Hypertrophic Scar Treatment with Triamcinolone Injection in Mekong Delta, Vietnam - A Cross-Sectional Study.
المؤلفون: Van Nguyen L; Department of Cosmetic Plastic Surgery, Faculty of Medicine, Can Tho University of Medicine and Pharmacy, Can Tho, Vietnam., Ly HQ; Department of Cosmetic Plastic Surgery, Faculty of Medicine, Can Tho University of Medicine and Pharmacy, Can Tho, Vietnam., Vo HT; Department of Cosmetic Plastic Surgery, Faculty of Medicine, Can Tho University of Medicine and Pharmacy, Can Tho, Vietnam., Pham TT; Department of Dermato-Venereology, Faculty of Medicine, Can Tho University of Medicine and Pharmacy, Can Tho, Vietnam., Nguyen NK; Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Can Tho University of Medicine and Pharmacy, Can Tho, Vietnam., Vo TV; Department of Pediatrics, Faculty of Medicine, Can Tho University of Medicine and Pharmacy, Can Tho, Vietnam., Phan TQ; Department of Cosmetic Plastic Surgery, Faculty of Medicine, Can Tho University of Medicine and Pharmacy, Can Tho, Vietnam., Tran PTN; Department of Cosmetic Plastic Surgery, Faculty of Medicine, Can Tho University of Medicine and Pharmacy, Can Tho, Vietnam., Ly HHV; Department of Orthopedics, Faculty of Medicine, Can Tho University of Medicine and Pharmacy, Can Tho, Vietnam., Mai HTT; Department of Cosmetic Plastic Surgery, Faculty of Medicine, Can Tho University of Medicine and Pharmacy, Can Tho, Vietnam.
المصدر: Clinical, cosmetic and investigational dermatology [Clin Cosmet Investig Dermatol] 2023 Nov 17; Vol. 16, pp. 3341-3348. Date of Electronic Publication: 2023 Nov 17 (Print Publication: 2023).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Dove Medical Press Country of Publication: New Zealand NLM ID: 101543449 Publication Model: eCollection Cited Medium: Print ISSN: 1178-7015 (Print) Linking ISSN: 11787015 NLM ISO Abbreviation: Clin Cosmet Investig Dermatol Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Auckland, NZ : Dove Medical Press
مستخلص: Background: Excessive scarring is a common problem that can have significant cosmetic and psychological consequences for patients. Intralesional injection therapy, such as the use of triamcinolone, has emerged as an effective treatment option for hypertrophic scars. The objective of this study was to describe the morphological features of hypertrophic scars, categorize them, and evaluate the efficacy of triamcinolone injection therapy in treating these scars.
Materials and Methods: A cross-sectional descriptive study of 80 patients with hypertrophic scars treated with triamcinolone intralesional injection at Can Tho University of Medicine and Pharmacy Hospital from 5/2018 to 5/2021.
Results: There were 80 patients in all, with a male/female ratio of 1/1.05 and a median age of 15-35. There were 129 scars in all, with scar age >1 year accounting for 83%, keloid scars accounting for 64%, and hypertrophic scars accounting for the remaining 36%. Scars are most commonly seen on the trunk, accounting for 53.5% of all scars, particularly on the anterior chest wall. When the source of scars was discovered, trauma and acne accounted for 24% and 23%, respectively, while the rest were predominantly spontaneous scars, accounting for 49%. Scarring and discomfort of mild to moderate severity were common clinical symptoms; scars larger than 5cm in size had more symptoms than scars smaller than 5cm. Prior to the therapy, the mean Vancouver Score Scale-VSS was 6.55±2.13. After 24 weeks of the therapy, 96.7% of patients had entirely improved itching symptoms, 75% had completely improved pain, and 25% still had minimal pain. After therapy, the mean Vancouver Score Scale-VSS was 2.55±1.81 (p<0.05). At week 24, 3.75% of patients experienced skin shrinkage, 3.75% experienced depigmentation, and 13.75% experienced vasodilation.
Conclusion: Triamcinolone intralesional injection should be utilized as a first-line therapy for hypertrophic scarring.
Competing Interests: The authors declare no conflicts of interest in this work.
(© 2023 Van Nguyen et al.)
References: Adv Wound Care (New Rochelle). 2019 Jan 1;8(1):7-13. (PMID: 30705785)
Int J Dermatol. 2018 Oct;57(10):1192-1200. (PMID: 29993130)
Niger J Clin Pract. 2019 Aug;22(8):1049-1054. (PMID: 31417046)
Burns. 2018 Sep;44(6):1482-1488. (PMID: 29886113)
Dermatol Pract Concept. 2022 Apr 01;12(2):e2022072. (PMID: 35646428)
J Plast Reconstr Aesthet Surg. 2019 Jan;72(1):4-11. (PMID: 30448246)
Matrix Biol. 2016 Apr;51:37-46. (PMID: 26844756)
J Dermatolog Treat. 2022 Feb;33(1):150-156. (PMID: 32063079)
Dermatol Surg. 2017 Jan;43 Suppl 1:S3-S18. (PMID: 27347634)
Int J Mol Sci. 2018 Mar 02;19(3):. (PMID: 29498630)
JAAD Case Rep. 2019 Sep 24;5(10):840-843. (PMID: 31646158)
Clin Cosmet Investig Dermatol. 2018 Jul 24;11:387-396. (PMID: 30087573)
J Cosmet Dermatol. 2019 Jun;18(3):874-878. (PMID: 29935013)
فهرسة مساهمة: Keywords: clinical features; hypertrophic scar; triamcinolone intralesional injection
تواريخ الأحداث: Date Created: 20231129 Latest Revision: 20231201
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC10661894
DOI: 10.2147/CCID.S432735
PMID: 38021426
قاعدة البيانات: MEDLINE
الوصف
تدمد:1178-7015
DOI:10.2147/CCID.S432735